Purzer Pharmaceutical Co., Ltd (Purzer) is a PIC/S GMP pharmaceutical and GMP medical device manufacturing ,established in 1988, with 200 employees and NT$420 million capital.
For years Purzer has been agressively invested in R&D, working with domestic and foreign R&D labs to develop competitive, high quality new products.
Purzer was the first Taiwan based pharmaceutical company to conduct α-1 Blocker clinical trial in Europe.
Purzer developed and launched calcitonin, an unique high-tech biologic preparation for treatment of osteoporosis.
Also, Purzer has developed and launched several modified release products, entering special pharmaceutics field through international cooperation.
In the future, Purzer will contuinue to strive for improving the health and living quality of mankind through improving its technical capability and products.